[THE INVESTOR] On Sept. 21, Whanin Pharm (016580) slightly edged up 0.63% to 16,100 won (US$ 14.38). It had declined 3.58% through the past month. Standard deviation, the variableness index, was 1.9% over the same period over one month.
![](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=640&simg=http://webchart.thinkpool.com/research/FArrowChart/A01658020160921.gif)
Compared with its close competitors within the same industry, KOSPI, even though the monthly earnings rate of Whanin Pharm was negative, its volatility for one month was lower than that of its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.8%. In spite of stock price decline, low volatility lead the return-on-risk to a high level. Moreover, compared with the KOSPI industry, the return-on-risk is much better than the industrial mean, -2.1, and thus the industrial comparison performance was positive.
As of Sept. 20, institutions have been buying for the past five trading days and foreigners have been buying for the past two trading days. As a shareholding sum by investor group for the past four weeks, foreigners have bought 17,139 shares and institutions have bought 113,269 shares with trending trade. However, during the same period, individuals have sold 130,408 shares with a decreasing position.
By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.